SG11201810580PA - Lipids with odd number of carbon atoms and their use as pharmaceutical composition or nutritional supplement - Google Patents
Lipids with odd number of carbon atoms and their use as pharmaceutical composition or nutritional supplementInfo
- Publication number
- SG11201810580PA SG11201810580PA SG11201810580PA SG11201810580PA SG11201810580PA SG 11201810580P A SG11201810580P A SG 11201810580PA SG 11201810580P A SG11201810580P A SG 11201810580PA SG 11201810580P A SG11201810580P A SG 11201810580PA SG 11201810580P A SG11201810580P A SG 11201810580PA
- Authority
- SG
- Singapore
- Prior art keywords
- diseases
- international
- lipids
- carbon atoms
- odd number
- Prior art date
Links
- 235000015872 dietary supplement Nutrition 0.000 title abstract 4
- 150000002632 lipids Chemical class 0.000 title abstract 4
- 125000004432 carbon atom Chemical group C* 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 102220240796 rs553605556 Human genes 0.000 abstract 8
- 201000010099 disease Diseases 0.000 abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 2
- 230000002265 prevention Effects 0.000 abstract 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 abstract 1
- 208000016192 Demyelinating disease Diseases 0.000 abstract 1
- 241001465754 Metazoa Species 0.000 abstract 1
- 208000028389 Nerve injury Diseases 0.000 abstract 1
- 241000737286 Ophioglossum Species 0.000 abstract 1
- 230000003712 anti-aging effect Effects 0.000 abstract 1
- 208000006673 asthma Diseases 0.000 abstract 1
- 210000004556 brain Anatomy 0.000 abstract 1
- 230000003925 brain function Effects 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 235000014113 dietary fatty acids Nutrition 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229930195729 fatty acid Natural products 0.000 abstract 1
- 239000000194 fatty acid Substances 0.000 abstract 1
- 150000004665 fatty acids Chemical class 0.000 abstract 1
- 235000013376 functional food Nutrition 0.000 abstract 1
- 208000017169 kidney disease Diseases 0.000 abstract 1
- 201000006938 muscular dystrophy Diseases 0.000 abstract 1
- 230000008764 nerve damage Effects 0.000 abstract 1
- 230000004770 neurodegeneration Effects 0.000 abstract 1
- 208000018360 neuromuscular disease Diseases 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 230000002207 retinal effect Effects 0.000 abstract 1
- 210000000278 spinal cord Anatomy 0.000 abstract 1
- 239000009853 xinfeng Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/225—Polycarboxylic acids
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/11—Pteridophyta or Filicophyta (ferns)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/11—Pteridophyta or Filicophyta (ferns)
- A61K36/12—Filicopsida or Pteridopsida
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Diabetes (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Pulmonology (AREA)
- Urology & Nephrology (AREA)
- Mycology (AREA)
- Botany (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Microbiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662347103P | 2016-06-08 | 2016-06-08 | |
| PCT/CN2017/087341 WO2017211274A1 (en) | 2016-06-08 | 2017-06-06 | Lipids with odd number of carbon atoms and their use as pharmaceutical composition or nutritional supplement |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201810580PA true SG11201810580PA (en) | 2018-12-28 |
Family
ID=60577583
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201810580PA SG11201810580PA (en) | 2016-06-08 | 2017-06-06 | Lipids with odd number of carbon atoms and their use as pharmaceutical composition or nutritional supplement |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US11406616B2 (enExample) |
| EP (1) | EP3468551A4 (enExample) |
| JP (2) | JP6872805B2 (enExample) |
| KR (1) | KR20190017873A (enExample) |
| CN (2) | CN117298092A (enExample) |
| AU (1) | AU2017277005B2 (enExample) |
| CL (1) | CL2018003537A1 (enExample) |
| MX (1) | MX2018015188A (enExample) |
| NZ (1) | NZ749389A (enExample) |
| SG (1) | SG11201810580PA (enExample) |
| TW (1) | TWI749016B (enExample) |
| WO (1) | WO2017211274A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112020004023A2 (pt) * | 2017-09-12 | 2020-09-08 | Sunregen Healthcare Ag | uso de um composto e composição farmacêutica ou suplemento nutricional |
| CN111773274A (zh) * | 2019-09-20 | 2020-10-16 | 厦门医学院 | 瓶尔小草及车前子组合物在制备降血糖及降血压的药物组合物中的应用 |
| CN111773351A (zh) * | 2019-09-20 | 2020-10-16 | 厦门医学院 | 瓶尔小草及姜黄组合物在制备降血糖及降血压的药物组合物中的应用 |
| US12485103B2 (en) | 2019-11-27 | 2025-12-02 | Refine Holdings Co., Ltd. | Insulin secretion-promoting agent and blood sugar level improver using same, diabetes improver, and food |
| WO2022263624A1 (en) * | 2021-06-18 | 2022-12-22 | Sunregen Healthcare Ag | Novel compounds for the treatment and prevention of neurological complications of viral infections |
| JP2023061448A (ja) * | 2021-10-20 | 2023-05-02 | リファインホールディングス株式会社 | 小胞体ストレス抑制剤、神経変性疾患予防改善剤および認知症の予防・進行防止・改善剤、並びに食品 |
| JPWO2024075625A1 (enExample) * | 2022-10-02 | 2024-04-11 |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS558351A (en) | 1978-07-05 | 1980-01-21 | Hitachi Ltd | Press machine |
| DE3032300A1 (de) | 1980-08-27 | 1982-04-01 | Alfred Ing. Wien Lohninger | Mittel zur parenteralen ernaehrung |
| JPS5919775U (ja) | 1982-07-26 | 1984-02-06 | ワイケイケイ株式会社 | カ−テンウオ−ルの断熱窓 |
| JPH02247125A (ja) * | 1989-03-17 | 1990-10-02 | Koken Kk | 悪性腫瘍細胞増殖抑制剤 |
| JP3558351B2 (ja) | 1992-12-07 | 2004-08-25 | 邦郎 辻 | 免疫抑制剤 |
| DE19821003A1 (de) * | 1998-05-11 | 1999-11-18 | Dresden Arzneimittel | Neue 1,2,5-trisubstituierte 1,2-dihydro-indazol-3-one mit antiasthmatischer, antiallergischer, entzündungshemmender, immunmodulierender und neuroprotektiver Wirkung, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| WO2001082928A1 (en) | 2000-05-01 | 2001-11-08 | Accera, Inc. | Use of medium chain triglycerides for the treatment and prevention of alzheimer's disease and other diseases resulting from reduced neuronal metabolism |
| ATE341331T1 (de) | 2000-06-14 | 2006-10-15 | William Leslie Porter | Lipide zur änderung des abwehrsystems |
| IL142535A0 (en) * | 2001-04-11 | 2002-03-10 | Yeda Res & Dev | Pharmaceutical compositions for the treatment of inflammation |
| EA007322B1 (ru) | 2001-04-18 | 2006-08-25 | Прометик Байосайенсиз, Инк. | Жирные кислоты со средней длиной цепи, глицериды и аналоги как факторы, способствующие выживанию и активации нейтрофилов |
| CN1764446A (zh) * | 2003-03-13 | 2006-04-26 | 康福玛医药公司 | 含有长链和中链甘油三酯的药物制剂 |
| EP1628622A4 (en) * | 2003-05-20 | 2008-12-17 | Baylor Res Inst | FIVE AND FIFTH CARBON FATTY ACIDS FOR THE TREATMENT OF METABOLISM DISORDERS AND AS FOOD SUPPLEMENTS |
| JP4334956B2 (ja) * | 2003-09-18 | 2009-09-30 | 株式会社ノエビア | 細胞賦活剤、美白剤、及び抗酸化剤 |
| CN101137369A (zh) * | 2005-02-09 | 2008-03-05 | 马库赛特公司 | 用于眼治疗的制剂 |
| US20080132571A1 (en) | 2006-09-26 | 2008-06-05 | Baylor Research Institute | Nutrient Sensor |
| EP1929995A1 (en) | 2006-12-04 | 2008-06-11 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Anaplerotic therapy of Huntington disease and other polyglutamine diseases |
| KR100829729B1 (ko) * | 2007-01-29 | 2008-05-15 | 한불화장품주식회사 | 병이소초 추출물을 주요 활성성분으로 함유하는 피부외용제 조성물 |
| RU2519215C2 (ru) | 2007-11-02 | 2014-06-10 | Прометик Байосайенсиз Инк. | Жирные кислоты и глицериды со средней длиной цепи в качестве нефропротективных средств |
| DE102008046227A1 (de) * | 2008-06-10 | 2009-12-17 | Ludwig-Maximilians-Universität München | Hochdurchsatzmethode zur Analyse der Fettsäurezusammensetzung in Plasmaphosphoglyceriden |
| DE102008057867A1 (de) | 2008-11-18 | 2010-05-20 | B. Braun Melsungen Ag | Fettemulsion zur künstlichen Ernährung von schwerkranken Intensivpatienten |
| CN101879156B (zh) | 2009-05-07 | 2013-01-30 | 上海医药工业研究院 | 一种药物组合物及其应用 |
| AU2010336921A1 (en) | 2009-12-30 | 2012-07-26 | Baylor Research Institute | Anaplerotic therapy for Alzheimer's disease and the aging brain |
| AR080357A1 (es) * | 2010-01-08 | 2012-04-04 | Catabasis Pharmaceuticals Inc | Derivados de fumaratos de acidos grasos, composiciones farmaceuticas y sus usos |
| US20130196937A1 (en) * | 2010-02-10 | 2013-08-01 | Oryza Oil & Fat Chemical Co., Ltd. | Age production inhibitor |
| US20110301238A1 (en) * | 2010-06-02 | 2011-12-08 | Borges Karin | Seizure related disorders and therapeutic methods thereof |
| AU2011267894A1 (en) | 2010-06-14 | 2012-12-20 | Baylor Research Institute | Triheptanoin diet for adult polyglucosan body disease (APBD) treatment |
| JP5836373B2 (ja) * | 2010-07-15 | 2015-12-24 | ヒブリジェニクス・エスアー | ビタミンｄの１４−エピ−アナログの新しい製剤 |
| EP2749281B1 (en) * | 2011-08-26 | 2018-03-28 | Osaka University | Prophylactic and/or therapeutic agent for cardiovascular complications of diabetes |
| CN102526643B (zh) * | 2012-03-22 | 2013-09-11 | 常熟市虞山绿茶有限公司 | 一种治疗口腔溃疡的中草药含片 |
| WO2014093901A1 (en) | 2012-12-13 | 2014-06-19 | Baylor Research Institute At Dallas | Triheptanoin for the treatment of glucose transporter 1 deficiency |
| ES2806701T3 (es) * | 2013-08-02 | 2021-02-18 | Swm Luxembourg Sarl | Producto comestible que comprende material vegetal reconstituido |
| AU2014348457B2 (en) * | 2013-11-14 | 2019-04-18 | The University Of Queensland | Neurodegenerative disorders and methods of treatment and diagnosis thereof |
| CN103641713B (zh) * | 2013-11-15 | 2015-10-21 | 浙江大学 | 甘油单酯衍生物的制备方法及应用 |
| WO2015110977A1 (en) | 2014-01-22 | 2015-07-30 | Rolexi Marketing (Pty) Ltd | Fatty acid composition and medicinal use thereof |
| CN104286296A (zh) * | 2014-09-25 | 2015-01-21 | 王美华 | 一种凉茶 |
| JP6406978B2 (ja) | 2014-11-04 | 2018-10-17 | 株式会社シー・アクト | 脂肪酸混合物 |
| CN105267501A (zh) * | 2015-11-04 | 2016-01-27 | 夏茂森 | 一种治疗毒蛇咬伤的中药组合物 |
| CN105381182A (zh) * | 2015-11-20 | 2016-03-09 | 冯天寿 | 一种治疗慢性荨麻疹的中药及其应用 |
| CN108289873A (zh) | 2015-12-04 | 2018-07-17 | 雀巢产品技术援助有限公司 | 用于改善认知的方法 |
-
2017
- 2017-06-06 SG SG11201810580PA patent/SG11201810580PA/en unknown
- 2017-06-06 NZ NZ749389A patent/NZ749389A/en unknown
- 2017-06-06 JP JP2018564968A patent/JP6872805B2/ja active Active
- 2017-06-06 TW TW106118787A patent/TWI749016B/zh active
- 2017-06-06 CN CN202311053636.8A patent/CN117298092A/zh active Pending
- 2017-06-06 EP EP17809713.5A patent/EP3468551A4/en active Pending
- 2017-06-06 WO PCT/CN2017/087341 patent/WO2017211274A1/en not_active Ceased
- 2017-06-06 CN CN201780036000.9A patent/CN110300581B/zh active Active
- 2017-06-06 AU AU2017277005A patent/AU2017277005B2/en active Active
- 2017-06-06 MX MX2018015188A patent/MX2018015188A/es unknown
- 2017-06-06 KR KR1020197000135A patent/KR20190017873A/ko not_active Ceased
- 2017-06-06 US US16/307,663 patent/US11406616B2/en active Active
-
2018
- 2018-12-07 CL CL2018003537A patent/CL2018003537A1/es unknown
-
2021
- 2021-04-13 JP JP2021067485A patent/JP2021113204A/ja active Pending
-
2022
- 2022-06-30 US US17/810,044 patent/US20220362197A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP6872805B2 (ja) | 2021-05-19 |
| KR20190017873A (ko) | 2019-02-20 |
| JP2021113204A (ja) | 2021-08-05 |
| CL2018003537A1 (es) | 2019-05-03 |
| TW201801720A (zh) | 2018-01-16 |
| JP2019518034A (ja) | 2019-06-27 |
| US20190255129A1 (en) | 2019-08-22 |
| US20220362197A1 (en) | 2022-11-17 |
| EP3468551A4 (en) | 2020-01-22 |
| NZ749389A (en) | 2022-12-23 |
| TWI749016B (zh) | 2021-12-11 |
| AU2017277005A1 (en) | 2019-01-17 |
| CN110300581A (zh) | 2019-10-01 |
| CA3026152A1 (en) | 2017-12-14 |
| CN117298092A (zh) | 2023-12-29 |
| WO2017211274A1 (en) | 2017-12-14 |
| AU2017277005B2 (en) | 2022-12-22 |
| EP3468551A1 (en) | 2019-04-17 |
| CN110300581B (zh) | 2023-09-08 |
| US11406616B2 (en) | 2022-08-09 |
| MX2018015188A (es) | 2019-08-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201810580PA (en) | Lipids with odd number of carbon atoms and their use as pharmaceutical composition or nutritional supplement | |
| SG11201907056XA (en) | Compositions and methods for the treatment of hemoglobinopathies | |
| SG11201809301YA (en) | Isoquinolin-3-yl carboxamides and preparation and use thereof | |
| SG11201908512YA (en) | Somatostatin modulators and uses thereof | |
| SG11201900349VA (en) | Somatostatin modulators and uses thereof | |
| SG11201908330PA (en) | Farnesoid x receptor agonists and uses thereof | |
| SG11201809627QA (en) | Anti pd-1 and anti-lag3 antibodies for cancer treatment | |
| SG11201811432WA (en) | Rna for cancer therapy | |
| SG11201901063SA (en) | Therapeutic agents for neurodegenerative diseases | |
| SG11201805300QA (en) | Heterocyclic compounds as immunomodulators | |
| SG11201811470PA (en) | Pyrazolopyrimidine derivatives as kinase inhibitor | |
| SG11201903946SA (en) | Devices and methods for slurry generation | |
| SG11201908919XA (en) | Combination therapies targeting pd-1, tim-3, and lag-3 | |
| SG11201803920TA (en) | Compounds and compositions useful for treating disorders related to ntrk | |
| SG11201804263PA (en) | Cancer treatment using 2-deoxy-2-fluoro-l-fucose in combination with a checkpoint inhibitor | |
| SG11201808222RA (en) | Methods of treatment of cholestatic diseases | |
| SG11201900554YA (en) | Spiro-lactam nmda modulators and methods of using same | |
| SG11201810371XA (en) | ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF | |
| SG11201903061YA (en) | Combination treatments comprising administration of imidazopyrazinones | |
| SG11201900558RA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201909680UA (en) | Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds | |
| SG11201810853UA (en) | Anti-tnfrsf25 antibodies | |
| SG11201900443VA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201900551WA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201900546UA (en) | Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof |